Evidence map›Paper›PMID 28274007›Full record

ArticleJournal of clinical and diagnostic research : JCDR2017

Facial Dysmorphism: An Unreported Teratogenicity with Levetiracetam.

Jyotsana Gupta, Sandhya Jain, Shalini Rajaram, Neerja Goel, Bindiya Gupta

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical and diagnostic research : JCDR, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Jyotsana GuptaSenior Resident, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital , Delhi, India .
Sandhya JainAssociate Professor, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital , Delhi, India .
Shalini RajaramDirector and Professor, Department of Obsetrics and Gynaecology, UCMS and GTB Hospital , Delhi, India .
Neerja GoelDirector and Professor, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital , Delhi, India .
Bindiya GuptaAssistant Professor, Department of Obstetrics and Gynaecology, UCMS and GTB Hospital , Delhi, India .
Guru Teg Bahadur Hospital · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levetiracetam (LEV) is a relatively newer anticonvulsant drug used to treat epilepsy and is approved by United States Food and Drugs Administration (USFDA). The drug binds to a synaptic vesicle glycoprotein and inhibits presynaptic calcium channels, thus reducing neurotransmitter release. Commonly reported side effects include drowsiness, weakness, unsteady gait, mood changes and loss of appetite. Like most other antiepileptics, it is a Category C drug in pregnancy. We report the first case of facial dysmorphism in the neonate of a mother taking LEV antenatally. A 30-year-old lady, G

Indexed as

Antiepileptic drugsBifid vertebraCategory C drugFacial dysmorphism

Identifiers

PMID28274007
PMCPMC5324452
OpenAlexW2587499252

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.